Evidence map›Paper›PMID 32383186›Full record

ArticleInternational journal of cancer2020

Oncogenic properties and signaling basis of the PAX8-GLIS3 fusion gene.

Thais Basili, Higinio Dopeso, Sarah H Kim, Lorenzo Ferrando, Fresia Pareja, Arnaud Da Cruz Paula, Edaise M da Silva, Anthe Stylianou, Ana Maroldi, Caterina Marchiò and 6 more

Open access · greenAbstract read
In one paragraph

Article in International journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Thais BasiliDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0003-3216-3544
Higinio DopesoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Sarah H KimDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Lorenzo FerrandoDepartment of Internal Medicine, University of Genoa, Genoa, Italy.
Fresia ParejaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Arnaud Da Cruz PaulaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Edaise M da SilvaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Anthe StylianouDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ana MaroldiDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Caterina MarchiòCandiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
Brian P RubinDepartment of Pathology, Cleveland Clinic, Cleveland, Ohio, USA.
Mauro PapottiDepartment of Oncology, University of Turin, at Città della Salute Hospital, Torino, Italy.
Britta WeigeltDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Carlos Gil Moreira FerreiraOncoclinicas Institute for Research and Education, Sao Paulo, Brazil.
José Roberto Lapa E SilvaFederal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Jorge S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0003-2969-3173
Memorial Sloan Kettering Cancer Center · USUniversidade Federal do Rio de Janeiro · BRAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITCandiolo Cancer Institute · ITCleveland Clinic · USUniversity of Genoa · IT

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
MSK Paul Calabresi Career Development Award for Clinical OncologyK12CA184746 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Omar Abdel-Wahab, Simon N. Powell · 2015 to 2026
$8.3M
NCI NIH HHS K12 CA184746NCI NIH HHS P30 CA008748NCI NIH HHS P30CA008748NIH HHS CA184746
6 · The paper itself

Abstract

Hyalinizing trabecular tumors of the thyroid are rare and mostly benign epithelial neoplasms of follicular cell origin, which have recently been shown to be underpinned by the PAX8-GLIS3 fusion gene. In our study, we sought to investigate the potential oncogenic mechanisms of the PAX8-GLIS3 fusion gene. Forced expression of PAX8-GLIS3 was found to increase proliferation, clonogenic potential and migration of human nonmalignant thyroid (Nthy-ori 3-1) and embryonic kidney (HEK-293) cells. Moreover, in xenografts, Nthy-ori 3-1 PAX8-GLIS3 expressing cells generated significantly larger and more proliferative tumors compared to controls. These oncogenic effects were found to be mediated through activation of the Sonic Hedgehog (SHH) pathway. Targeting of smoothened (SMO), a key protein in the SHH pathway, using the small molecule inhibitor Cyclopamine partially reversed the increased proliferation, colony formation and migration in PAX8-GLIS3 expressing cells. Our data demonstrate that the oncogenic effects of the PAX8-GLIS3 fusion gene are, at least in part, due to an increased activation of the SHH pathway.

Indexed as

AnimalsCarcinogenesisCell MovementCell ProliferationDNA-Binding ProteinsFemaleHedgehog ProteinsHEK293 CellsHeterograftsHumansMiceMice, NudeOncogene Proteins, FusionOncogenesPAX8 Transcription FactorRepressor ProteinsDNA-Binding ProteinsGLIS3 protein, humanHedgehog ProteinsOncogene Proteins, FusionPAX8 protein, humanPAX8 Transcription FactorRepressor ProteinsTrans-Activatorsfusion genehyalinizing trabecular tumorsonic hedgehog pathwaythyroid

Identifiers

PMID32383186
PMCPMC7679121
OpenAlexW3022916784

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.